Research in brief

ABSTRACT

A nasal monoclonal antibody Investigations following a pilot trial of foralumab, the nasal monoclonal antibody a monoclonal antibody develop for inflammatory conditions and now repurposed for COVID-19, revealed decreased inflammatory markers and the same gene expression modulation seen in patients with multiple sclerosis. A subsequent gene expression analysis found changes in gene expression patterns (including NKG7, TGF beB1 and GIMAP7) involved with the anti-inflammatory effects of the drug, not only in COVID-19 patients, but also in a patient with multiple sclerosis, meaning the drug may be used for several diseases. For more on COVID-19 drug resistance see Sci Adv 2023;published online March 29. https//www.science.org/doi/10.1126/sciadv.ade8778 For more on the new target for COVID-19 drugs see eLife 2023;published online March 21. https//doi.org/10.7554/eLife.83710 For more on the nasal monoclonal antibody see Proc Natl Acad Sci USA 2023;published online March 7. https//doi.org/10.1073/pnas.2220272120 For more on antibodies for yellow fever see Sci Transl Med 2023;published online March 29. https//doi.org/10.1126/scitranslmed.ade5795 For more on a new drug for mpox see J Med Virol 2023;published online March 10. https//doi.org/10.1002/jmv.28652 For more on the transmission of bacterial vaginosis see Cell Rep Med 2023;published online March 21. https//doi.org/10.1016/j.xcrm.2023.100981 For more on endolysin see J Invest Dermatol 2023;published online March 6. https//doi.org/10.1016/j.jid.2023.01.039